DREAMM Data Sets GSK’s Blenrep Up For Second Line Myeloma Dominance

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.